{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:16:57Z","timestamp":1788898617992,"version":"build-2803163510"},"reference-count":76,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"European Union \u2013 Next Generation EU","award":["NRRP M6C2 \u2013 Investment 2.1"],"award-info":[{"award-number":["NRRP M6C2 \u2013 Investment 2.1"]}]},{"name":"NHS biomedical research","award":["PNRR-MAD-2022\u201312376656"],"award-info":[{"award-number":["PNRR-MAD-2022\u201312376656"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14728214.2026.2693701","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:52:23Z","timestamp":1781949143000},"page":"107-121","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating emerging amyloid-\u03b2 centric drugs for the treatment of Alzheimer's disease"],"prefix":"10.1080","volume":"31","author":[{"given":"Madia","family":"Lozupone","sequence":"first","affiliation":[{"name":"Local Health Authority of Bari","place":["Bari, Italy"]},{"name":"University of Bari Aldo Moro","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9880-0481","authenticated-orcid":false,"given":"Vittorio","family":"Dibello","sequence":"additional","affiliation":[{"name":"University of Bari \u201cAldo Moro\u201d","place":["Bari, Italy"]},{"name":"University of Amsterdam and Vrije Universiteit Amsterdam","place":["Amsterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Sardone","sequence":"additional","affiliation":[{"name":"Local Healthcare Authority of Taranto","place":["Taranto, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zupo","sequence":"additional","affiliation":[{"name":"University of Bari \u201cAldo Moro\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Castellana","sequence":"additional","affiliation":[{"name":"University of Bari \u201cAldo Moro\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bortone","sequence":"additional","affiliation":[{"name":"Local Healthcare Authority of Taranto","place":["Taranto, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Lampignano","sequence":"additional","affiliation":[{"name":"University of Bari \u201cAldo Moro\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Di Matteo","sequence":"additional","affiliation":[{"name":"Local Health Authority of Bari","place":["Bari, Italy"]},{"name":"University of Bari Aldo Moro","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Moramarco","sequence":"additional","affiliation":[{"name":"Local Health Authority of Bari","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Dellegrazie","sequence":"additional","affiliation":[{"name":"Local Healthcare Authority of Bari","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Daniele","sequence":"additional","affiliation":[{"name":"Catholic University of Sacred Heart","place":["Rome, Italy"]},{"name":"IRCCS Fondazione Policlinico Universitario A. Gemelli","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Solfrizzi","sequence":"additional","affiliation":[{"name":"University of Bari \u201cAldo Moro\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-0656","authenticated-orcid":false,"given":"Francesco","family":"Panza","sequence":"additional","affiliation":[{"name":"Local Health Authority of Bari","place":["Bari, Italy"]},{"name":"University of Bari \u201cAldo Moro\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305032"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00426-0"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2025.2500752"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2025.2481847"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70098"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101959"},{"key":"e_1_3_4_11_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/www.ctad-alzheimer.com"},{"key":"e_1_3_4_12_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/aaic.alz.org"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00872-7"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75204-8"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"e_1_3_4_16_1","volume-title":"Early alzheimer\u2019s disease: developing drugs for treatment \u2013 guidance for industry","year":"2025","unstructured":"Early alzheimer\u2019s disease: developing drugs for treatment \u2013 guidance for industry. Silver Spring (MD): FDA; 2025 [cited 2026 Jan 24]. Available from: https:\/\/www.fda.gov"},{"key":"e_1_3_4_17_1","unstructured":"EMA\/CHMP. Revision. 2025 [cited 2026 Apr 22]. Available from: https:\/\/www.ema.europa.eu"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002609"},{"key":"e_1_3_4_19_1","unstructured":"Precedence Research. Alzheimer\u2019s therapeutics market size share growth 2024\u20132032. 2024 [cited 2026 Apr 22]. Available from: https:\/\/www.precedenceresearch.com\/alzheimers-therapeutics-market"},{"key":"e_1_3_4_20_1","unstructured":"DelveInsight. Anti-amyloid beta monoclonal antibodies market: insights epidemiology and forecast to 2032. 2024. Available from cited 2026 Apr 22]. Available from: https:\/\/www.delveinsight.com\/report-store\/anti-amyloid-beta-monoclonal-antibodies-market"},{"key":"e_1_3_4_21_1","unstructured":"Market Data Forecast. Alzheimer\u2019s drug market by mechanism of action global forecast 2024\u20132030. 2024 [cited 2026 Apr 22]. Available from: https:\/\/www.marketdataforecast.com"},{"key":"e_1_3_4_22_1","unstructured":"InsightAce Analytic. Alzheimer\u2019s therapeutics market forecast 2025\u20132035. 2025 [cited 2026 Apr 22]. Available from: https:\/\/www.insightaceanalytic.com"},{"key":"e_1_3_4_23_1","unstructured":"DelveInsight. Alzheimer\u2019s disease market report: epidemiology market forecasts and trends across 7 major markets (7MM). 2025. Available from cited 2026 Apr 22]. Available from: https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-market"},{"key":"e_1_3_4_24_1","unstructured":"Business Research Insights. Global dementia drugs market size share and forecast (2025\u20132030). 2025 [cited 2026 Apr 22]. Available from: https:\/\/www.businessresearchinsights.com"},{"key":"e_1_3_4_25_1","unstructured":"Eisai Co. Ltd. Eisai projects Leqembi revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025\u2013March 2026). PR Newswire\/Eisai news release. 2025 [cited 2026 Apr 22]. Available from: https:\/\/www.prnewswire.com\/news-releases\/eisai-projects-leqembi-revenue-to-total-jpy-76-5-billion-for-fiscal-year-2025-april-2025--march-2026-302456444.html"},{"key":"e_1_3_4_26_1","unstructured":"Eisai Co. Ltd. Eisai reports Leqembi (lecanemab) Q1 revenue and business update. Corporate news\/earnings release. 2024 [cited 2026 Apr 22]. Available from: https:\/\/www.eisai.com\/news\/2024\/news202458.html"},{"key":"e_1_3_4_27_1","unstructured":"BioSpace. Eisai lowers sales expectations for leqembi citing slow US uptake; FY2027 targets adjusted. BioSpace business report. 2024\u20132025 [cited 2026 Apr 22]. Available from: https:\/\/www.biospace.com\/business\/eisai-lowers-sales-expectations-for-leqembi-again-citing-slow-us-uptake"},{"key":"e_1_3_4_28_1","unstructured":"Investors Business Daily (or similar investor\/analyst press coverage). Analyst estimates for donanemab\u2014early sales scenarios and sensitivity to reimbursement. Public investor\/press analysis. 2024\u20132025 [cited 2026 Apr 22]. Available from: https:\/\/www.investors.com\/news\/technology\/eli-lilly-stock-alzheimers-treatment-donanemab-leqembi\/"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12376"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.3869"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14425"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00893-5"},{"key":"e_1_3_4_36_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/adpd.kenes.com"},{"key":"e_1_3_4_37_1","unstructured":"European Medicines Agency. Leqembi recommended for treatment of early alzheimer\u2019s disease. 2024 [cited 2025 Jan 15]. Available from:https:\/\/www.ema.europa.eu\/en\/news\/leqembi-recommendedtreatment-early-alzheimers-disease"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905"},{"key":"e_1_3_4_40_1","unstructured":"Eisai. Eisai presents new leqembi (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer\u2019s disease from additional analyses of clarity AD at the clinical trials on alzheimer\u2019s disease (CTAD) conference. [cited 2025 Jan 15]. Available from: https:\/\/www.eisai.com\/news"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14576"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-240171"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100446"},{"key":"e_1_3_4_45_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/www.alz.org\/news\/2025\/european-medicines-agency-recommends-kisunla-donanemab?"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2515414"},{"key":"e_1_3_4_47_1","unstructured":"Alzforum. [cited 2025 Mar 12]. Available from: https:\/\/www.alzforum.org\/therapeutics\/trontinemab"},{"key":"e_1_3_4_48_1","volume-title":"Presented at: International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases","author":"Jin Y","year":"2023","unstructured":"Jin Y, Gueorguieva I, Cheng YJ, et al. Safety and amyloid plaque reduction effects of remternetug in patients with alzheimer\u2019s disease: interim analysis from a phase 1 study. In: Presented at: International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases; Gothenburg, Sweden; 2023."},{"key":"e_1_3_4_49_1","volume-title":"Presented at: 2023 AD\/PD Conference","author":"Jin Y","unstructured":"Jin Y. Safety and amyloid plaque reduction effects of remternetug in patients with alzheimer\u2019s disease: interim analysis from a phase 1 study. In: Presented at: 2023 AD\/PD Conference; Gothernburg, Sweden; Mar."},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104665"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.03.005"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2018.34"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02250-5"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2011.20612"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100469"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100016"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.848215"},{"key":"e_1_3_4_58_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/www.promisneurosciences.com\/investors\/news-events\/press-releases\/detail\/232\/promis-neurosciences-presents-positive-data-from-pmn310"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70184"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf294"},{"key":"e_1_3_4_61_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/medically.roche.com\/content\/dam\/pdmahub\/restricted\/neurology\/aaic-2025\/AAIC-2025-poster-tortelli-gABriella-a-phase-2a-study-investigating-the-gamma-secretase-modulator"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt60"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph19010026"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.060393"},{"key":"e_1_3_4_65_1","unstructured":"TrueBinding Inc. Phase 1\/2 trial summary of TB006 in alzheimer\u2019s disease. Available from: https:\/\/www.alzforum.org\/therapeutics\/tb006"},{"key":"e_1_3_4_66_1","unstructured":"Verywell Health. Injectable alzheimer\u2019s drugs could save patients trips to the hospital. 2025 [cited 2025 Jul 18]. Available from: https:\/\/www.verywellhealth.com\/injectable-alzheimers-drugs-8776312"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5764-DN-2024-0204"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.78166"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04273-1"},{"key":"e_1_3_4_70_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/www.alzforum.org\/therapeutics\/dnl919"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00435-y"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac433"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5205"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01053-8"},{"key":"e_1_3_4_75_1","unstructured":"The Times. NHS to block best-ever Alzheimer\u2019s drug due to high costs. 2025 [cited 2025 Jan 15]. Available from: https:\/\/www.thetimes.com\/uk\/healthcare\/article\/nhs-to-block-best-ever-alzheimers-drug-due-to-high-costs-vkntlk0jw"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2025.01055"},{"key":"e_1_3_4_77_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/www.alz.org\/news\/2025\/fda-clearance-blood-test-primary-care-rule-out-alzheimers-related-amyloid-pathology?"},{"key":"e_1_3_4_78_1","unstructured":"[cited 2026 Apr 22]. Available from: https:\/\/www.roche.com\/investors\/updates\/inv-update-2025-10-13b"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2693701","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14728214.2026.2693701","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2693701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:23:08Z","timestamp":1788258188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2026.2693701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14728214.2026.2693701"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2026.2693701","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}